Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

LEQEMBI IQLIK

LECANEMAB-IRMB

Standard Dose
360MG/1.8ML(200MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview LEQEMBI IQLIK is listed in Drugs@FDA under application 761375 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient LECANEMAB-IRMB Form and strength INJECTABLE;SUBCUTANEOUS - 360MG/1.8ML(200MG/ML) Sponsor EISAI INC Submission history Latest submission status date: 2025-08-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview LEQEMBI IQLIK is listed in Drugs@FDA under application 761375 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient LECANEMAB-IRMB Form and strength INJECTABLE;SUBCUTANEOUS - 360MG/1.8ML(200MG/ML) Sponsor EISAI INC Submission history Latest submission status date: 2025-08-29 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.